Results 251 to 260 of about 64,289 (299)
Some of the next articles are maybe not open access.
Intraperitoneal chemotherapy for colorectal cancer
Journal of Surgical Oncology, 2001AbstractThe peritoneal surface remains an important failure site for patients with colorectal cancer. Peritoneal metastases of colorectal cancer are at present considered equal to distant metastatic disease. Consequently, peritoneal carcinomatosis is treated with systemic chemotherapy and surgery only to palliate complications such as obstruction ...
Eelco, de Bree +2 more
openaire +2 more sources
Intraperitoneal chemotherapy for ovarian cancer
Current Opinion in Oncology, 2006Intraperitoneal chemotherapy for ovarian cancer is based on sound pharmacological principles and is technically feasible. There is mounting evidence, bolstered by a recent randomized trial, that in certain patients, this route of delivery may be superior to traditional intravenous chemotherapy.
Chad A, Hamilton, Jonathan S, Berek
openaire +2 more sources
Carrier solutions for intraperitoneal chemotherapy
Surgical Oncology Clinics of North America, 2003Two pharmacokinetic problems appear to limit the effectiveness of intraperitoneal therapy: poor tumor penetration and nonuniform intraperitoneal distribution by the drug-containing solution. A better understanding of the pharmacodynamics of carrier solutions for intraperitoneal chemotherapy may impact on both these problems.
Faheez, Mohamed, Paul H, Sugarbaker
openaire +2 more sources
Intraperitoneal regional chemotherapy with mitroxantrone
1996Pharmacokinetic considerations and tests with cell lines and individual cell suspensions from metastatic human solid tumor biopsies suggested testing the efficacy of mitoxantrone (NOV) in intraperitoneal regional chemotherapy (IPRC). Twenty-seven patients with intraperitoneal metastatic disease of various solid tumors received cyclic IPRC with NOV for ...
K H, Link +5 more
openaire +2 more sources
Intraperitoneal chemotherapy for ovarian cancer
Current Oncology Reports, 2003Intraperitoneal chemotherapy provides a means by which high concentrations of drugs and long durations of tissue exposure can be attained at the peritoneal surface. It has been studied widely in ovarian cancer, a disease in which intra-abdominal progression remains the major source of morbidity and mortality.
Gregory, Friberg, Gini, Fleming
openaire +2 more sources
Intraperitoneal chemotherapy in ovarian cancer
Cancer Treatment Reviews, 2000From a theoretical viewpoint, intraperitoneal therapy (IP) in patients with ovarian cancer, a malignancy which remains mainly confined to the peritoneal cavity, is logical. Over the past decades this approach has evolved into a therapeutic strategy for a selected group of patients.
L S, Hofstra +3 more
openaire +2 more sources
Adjuvant Intraperitoneal Chemotherapy: A Review
2007The rationale for adding perioperative chemotherapy to the management of gastrointestinal and ovarian cancer was developed by Cunliffe and Sugarbaker in 1989. They based the rationale for this novel approach on the patterns of recurrence of both gastrointestinal and ovarian cancer [1].
openaire +2 more sources
Imaging in Hyperthermic Intraperitoneal Chemotherapy
RadioGraphicsImaging plays an integral role in the management of patients undergoing hyperthermic intraperitoneal chemotherapy, enabling accurate patient selection, estimation of the peritoneal carcinomatosis index and completeness of cytoreduction score, and evaluation of postprocedural complications.
Shravya Srinivas Rao +6 more
openaire +2 more sources
[Intraperitoneal chemotherapy].
Gan to kagaku ryoho. Cancer & chemotherapy, 1989A fact that the Second International Conference of Intracavitary Chemotherapy was held at Sandiego in 1988 clearly suggests that the intraperitoneal chemotherapy attracts again the attention as a new administration route aimed at complete cure and useful modality against refractory intraabdominal cancer.
openaire +1 more source